SCHEMBL2207115

SCHEMBL2207115

COc1cc2c(cc1[N+](=O)[O-])N(C(=O)CCl)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.50
HTR1D P28221 2/20 0.50
HTR1B P28222 2/20 0.50
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 2/20 0.43
PLK1 P53350 3/20 0.42
ABCB1 P08183 2/20 0.41
ABCC1 P33527 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
MITF O75030 1/20 0.41
XBP1 P17861 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CASP3 P42574 1/20 0.40
CASP2 P42575 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20939751 0.95 HTR1A (0.48) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2203592 0.88 HTR1A (0.52) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2205322 0.88 HTR1A (0.50) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2201991 0.86 PLK1 (0.54) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2206786 0.85 SMN1; SMN2 (0.53) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2206626 0.85 MEN1 (0.53) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL23817954 0.85 ALDH1A1 (0.50) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2204135 0.84 HTR1A (0.47) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2206603 0.84 HTR1A (0.47) HTR1AHTR1DHTR1BMEN1KMT2A
SCHEMBL2209631 0.82 KMT2A (0.47) HTR1AHTR1DHTR1BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188292-B1 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER GLAXOSMITHKLINE IP DEV LTD (GB) 2013-05-29 EP disclosed
US-7981903-B2 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer GLAXOSMITHKLINE LLC (US) 2011-07-19 US disclosed
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer GLAXOSMITHKLINE LLC 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer IGF1R, IGFBP2, IGFBP1 HTR1A 1439/4885HTR1D 740/4885HTR1B 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.